China Touyun Tech Group (1332) AI Stock Analysis

• Market Cap: HK$246.92M
• Dividend Yield: N/A
• Average Volume (3M): 910.31K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.11
• Revenue Growth: -19.47%
• EPS Growth: 67.26%
• Country: HK
• Employees: 485
• Sector: Industrials
• Sector Strength: 84
• Industry: Packaging & Containers
• EPS (TTM): -0.03
• Shares Outstanding: 2,805,952,100
• 10 Day Avg. Volume: 101,718
• 30 Day Avg. Volume: 910,312
• PEG Ratio: -0.09
• Price to Book (P/B): -5.77
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 29 Underperform
• Price Target: ―

The overall score reflects significant financial distress with negative equity and cash flow issues as primary concerns. The bearish technical indicators and unfavorable valuation metrics further weigh on the stock. Immediate strategic measures are necessary to address financial and operational inefficiencies.

China Touyun Tech Group Business Overview & Revenue Model

Company Description

Touyun Biotech Group Limited, an investment holding company, designs, develops, manufactures, and sells packaging products in Hong Kong, the People's Republic of China, Europe, North and South America, and internationally. It operates through four segments: QR Code Business, Packaging Products, Treasury Investment, and Chlamydomonas Reinhardtii Product Business. The QR Code Business segment provides QR codes on product packaging and solutions, and advertising display services. The Packaging Products segment manufactures and sells watch and jewelry boxes, eyewear cases, bags and pouches, and display units. The Treasury Investment segment invests and trades in securities, as well as offers money lending, placing and underwriting, securities brokerage, asset management, and margin financing services. The Chlamydomonas Reinhardtii Product Business segment produces and sells chlamydomonas reinhardtii, micro-algae, and related products. It also provides business intelligence IT solutions, online advertising display, and corporate management services. The company was formerly known as China Touyun Tech Group Limited and changed its name to Touyun Biotech Group Limited in May 2021. Touyun Biotech Group Limited was founded in 1989 and is headquartered in Wan Chai, Hong Kong.

How the Company Makes Money

China Touyun Tech Group generates revenue through multiple streams. The primary source of income is the manufacturing and sales of QR code packaging products, which are widely used by businesses for product tracking and consumer engagement. Additionally, the company offers integrated O2O marketing services, helping businesses connect with their customers through digital platforms. This includes providing QR code-based solutions that enhance brand interaction and customer experience. The group also engages in developing mobile games, contributing to its revenue through game sales and in-app purchases. The company's earnings are further supported by strategic partnerships and collaborations that expand its market reach and technological capabilities.

China Touyun Tech Group Financial Statement Overview

Summary

China Touyun Tech Group faces significant financial challenges with declining revenues, negative profitability, and a strained balance sheet. Negative equity and high leverage pose substantial risks, while cash flow constraints limit strategic options. The company must address operational inefficiencies and stabilize its financial position to improve its financial health.

Income Statement

The income statement reflects a challenging financial position with declining revenues and negative profit margins. The gross profit margin is positive but has deteriorated over time, indicating rising costs or pricing pressures. EBIT and EBITDA margins are negative, suggesting operational inefficiencies or high fixed costs. Net income remains negative, highlighting ongoing profitability challenges.

Balance Sheet

The balance sheet shows significant financial stress with negative stockholders' equity, indicating insolvency. The debt-to-equity ratio is not meaningful due to negative equity, but total debt is substantial compared to assets. Despite a decrease in total assets, liabilities have increased, further weakening the financial position. The equity ratio is negative, emphasizing the company's reliance on debt financing.

Cash Flow

Cash flow analysis reveals weak operational cash generation with zero operating cash flow in the latest period. Free cash flow has been negative, indicating cash burn and insufficient cash flow to cover capital expenditures. The absence of recent positive cash flow metrics limits financial flexibility and investment capacity.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
159.97M	198.64M	315.82M	283.50M	206.79M
	Gross Profit
72.07M	56.60M	120.12M	107.05M	84.61M
	EBIT
-67.58M	-90.32M	-26.55M	-35.30M	-73.17M
	EBITDA
-27.92M	-228.57M	-144.39M	-83.13M	-87.22M
	Net Income Common Stockholders
-88.11M	-268.94M	-202.66M	-123.94M	-171.99M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
69.64M	36.04M	144.25M	93.95M	254.40M
	Total Assets
550.32M	607.34M	887.70M	1.02B	971.94M
	Total Debt
384.59M	384.91M	395.01M	317.37M	222.62M
	Net Debt
368.27M	350.42M	266.92M	257.17M	80.18M
	Total Liabilities
590.96M	586.27M	604.19M	537.68M	415.57M
	Stockholders Equity
-83.20M	-848.00K	263.96M	469.92M	488.04M
Cash Flow		Free Cash Flow
0.00	-13.49M	-39.30M	-304.60M	-140.86M
	Operating Cash Flow
0.00	3.65M	-26.37M	-53.81M	-15.35M
	Investing Cash Flow
0.00	-70.95M	-17.25M	-147.74M	-47.87M
	Financing Cash Flow
0.00	-27.68M	102.63M	123.17M	160.47M

China Touyun Tech Group Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.09
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1332, the sentiment is Neutral. The current price of 0.09 is above the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.13, and below the 200-day MA of 0.16, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 32.91 is Neutral, neither overbought nor oversold. The STOCH value of 64.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1332.

China Touyun Tech Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	66 Neutral	$4.44B	12.08	5.34%	5.82%	4.17%	-11.81%
6898	64 Neutral	HK$640.97M	34.72	17.56%	0.83%	-3.27%	-16.88%
1626	55 Neutral	HK$1.78B	75.52	1.47%	1.39%	-47.79%	-78.74%
0252	52 Neutral	HK$362.93M	21.50	1.55%	1.86%	-1.96%	-45.69%
1820	44 Neutral	HK$1.20B	416.67	-3.49%	2.00%	4.56%	-186.08%
8291	32 Underperform	HK$14.24M	―		―	11.10%	74.59%
1332	29 Underperform	HK$246.92M	―	-335.55%	―	-19.47%	67.26%

China Touyun Tech Group Corporate Events

Touyun Biotech Group Proposes New Share Option Scheme

Touyun Biotech Group Limited has announced its intention to adopt a new share option scheme while terminating the existing one, which was initially adopted in June 2022. The new scheme aims to align with the amended Chapter 17 of the Listing Rules effective from January 2023, and is designed to attract and retain high-caliber personnel by providing additional incentives and promoting the company’s long-term growth and profitability. The adoption of the new scheme is subject to shareholder approval and regulatory permissions.

Touyun Biotech Reports Reduced Losses for 2024

Touyun Biotech Group Limited reported its annual results for the year ending December 31, 2024, showing a significant reduction in losses compared to the previous year. The company achieved a gross profit of HK$62.8 million, up from HK$56 million in 2023, despite a decrease in revenue from sales of goods and services. The improvement in financial performance is attributed to a fair value gain on financial assets and increased interest income from its money lending business, although the company still reported an overall loss of HK$88 million.

Touyun Biotech Schedules Board Meeting for Annual Results and Dividend Decision

Touyun Biotech Group Limited has announced that its board of directors will meet on March 26, 2025, to approve the company’s annual results for the year ending December 31, 2024, and to consider the payment of a final dividend. This meeting is significant as it will determine the company’s financial performance and shareholder returns, potentially impacting its market position and investor relations.